Abstract
Schizophrenia is a complex neuropsychiatric disorder developed by genetic and environmental factors. The treatment is based on antipsychotics, such as risperidone. Some of illness symptoms has been mimic by MK-801, a non-competitive antagonist of glutamate NMDA receptor. Proteome evidences have been shown disturbances in oligodendrocytes metabolism of schizophrenia patients, mainly in energy metabolism. The aim of this study is to characterize the proteome of a human oligodendrocyte cell line treated with MK-801, risperidone and the co-treatment, in order to shed light about the interactions between schizophrenia and the antipsychotic drug risperidone.
Highlights
These proteins were mainly related with cellular process, metabolic process and cellular component organization or biogenesis
For the cotreatment (MK801+Risperidone) we identified 1250 proteins wich 88 were present at different levels
Most of these proteins were related with cellular process, metabolic process and cellular component organization or biogenesis
Summary
Schizophrenia is a multifactorial psychiatric disease that affects 1% of the world's population. The symptoms include hallucinations, cognitive dysfunction and social isolation; which are treated with antipsychotic, such as risperidone[1]. Strong evidences have been shown the hypofunction of NMDA glutamate receptor and glutamatergic dysfunction in patients with schizophrenia[2]. MK-801, a NMDA receptor antagonist, has been employed in cell culture to mimic this dysfunctions in glutamate neurotransmission. The loss of oligodendrocytes as well as the decrease of myelination in prefrontal cortex of schizophrenia patients have been reported[4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
